放化疗同步与单纯放疗治疗胶质母细胞瘤的疗效比较

目的 比较单纯放疗(RT)与放疗加替莫唑胺(RT-TMZ)治疗胶质母细胞瘤的局控率、生存率及不良反应.方法 对60例首次术后的胶质母细胞瘤随机分为接受单纯放疗、放疗加每天持续的替莫唑胺治疗以及6个周期的替莫唑胺辅助治疗.每组30例.主要研究目标为整体生存率.结果 RT-TMZ组与RT组总有效率分别为53.3%和26.6%;1年累计局部复发率分别为63.3%和90.0%,1年无复发生存率分别为36.7%和10.0%,1年生存率分别为56.7%和16.7%(P<0.05).RT-TMZ组常见不良反应是恶心,呕吐,白细胞和血小板下降,但仅限于Ⅰ～Ⅱ度.结论 在提高局控率、延缓肿瘤复发与提高患者无瘤生存期方面RT-TMZ组要优于RT组,而不良反应方面两组反应均较轻微.

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Objective To compare the rate of local eontrol, survival and safety in patients receiving radiotherapy alone (RT) and radiotherapy plus concomitant and adjuvant temozolomide (RT-TMZ) in postoperative patients with glioblastoma. Method 60 postoperative patients with glioblastoma were randomly divided into two groups: RT Group and RT-TMZ Group, each group have 30 patients. The primary end point was overall survial. Results The overall response rate in RT-TMZ Group and RT Group were 53.3% and 26. 6% respeetively. The one-year cumulative local failure rate was 63.3% and 90. 0% respeetively. The one-year free from local failure survival rate was 36.7% and 10. 0% respectively, The one-year survival rate was 56.7% and 16.7% respectively ( P < 0. 05 ). The main side-effect including nausea, vomiting, leueopema, and thrombocytopenia were not serious (grade Ⅰ～Ⅱ ). Conclusions The RT-TMZ Group was well in local control rate, delaying relapse and increasing relapse free survival rate compared with RT Group. The side-effect were little in both groups.